56 Results for "

CKDs

" in MedChemExpress (MCE) Product Catalog:
Products (56)

56 Results for "CKDs" in MCE Product Catalog:

44
44 Publications Verification
Cat. No.: HY-13324
CAS No.: 218600-53-4
Purity:  98.92%
Synonyms: RTA 402; NSC 713200; CDDO Methyl ester
Bardoxolone methyl (RTA 402) is an orally active and blood-brain-barrier-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC50 value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N1428C
CAS No.: 3522-50-7
Synonyms: Iron(III) citrate; Zerenex
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-126397
CAS No.: 55266-18-7
Purity:  ≥98.0%
Target:  

NF-κB

Research Areas:  

Inflammation/Immunology

MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13566A
CAS No.: 213819-48-8
Purity:  99.88%
Synonyms: CKD-602
Target:  

Topoisomerase

Research Areas:  

Cancer

Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13566
CAS No.: 256411-32-2
Purity:  99.86%
Synonyms: CKD-602 free base
Target:  

Topoisomerase Apoptosis

Research Areas:  

Cancer

Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N2995
CAS No.: 137551-38-3
Synonyms: Poricoic acid A(F)
Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109136
CAS No.: 1402936-61-1
Purity:  99.31%
Synonyms: BAY 1101042
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109109
CAS No.: 1246374-97-9
Purity:  98.66%
Synonyms: CKD-581
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145150
CAS No.: 2265215-18-5
Purity:  98.97%
Target:  

TRP Channel

Research Areas:  

Metabolic Disease

TRPC5-IN-1 (Compound 6j) is a selective TRPC5 inhibitor with 50.5 % Inhibition for TRPC5 at 3 μM. TRPC5-IN-1 can be used for the research of chronic kidney disease (CKD) .
loading...
    loading...
Cat. No.: HY-13102
CAS No.: 348622-88-8
Purity:  99.92%
Research Areas:  

Others

UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC50 value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring .
loading...
    loading...
Cat. No.: HY-112671
CAS No.: 1191265-33-4
Purity:  99.71%
Synonyms: RTA dh404
CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .
loading...
    loading...
Cat. No.: HY-113493
CAS No.: 82-82-6
Purity:  99.82%
4-Pyridoxic acid is an endogenous substrate of renal organic anion transporters (OAT1/3) and a catabolite of vitamin B6. 4-Pyridoxic acid is excreted through OAT1/3-mediated tubular active secretion, which can reflect OAT1/3 activity. Elevated plasma concentrations of 4-Pyridoxic acid are associated with decreased OAT1/3 activity in chronic kidney disease (CKD) and can be used as a biomarker to reflect the severity of knee osteoarthritis (KOA) and lumbar spondylosis (LS) .
loading...
    loading...
Cat. No.: HY-P11178
CAS No.: 2651277-02-8
Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF) .
loading...
    loading...
Cat. No.: HY-119572
CAS No.: 17141-74-1
Purity:  ≥95.0%
Research Areas:  

Inflammation/Immunology

Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K + in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD) .
loading...
    loading...
Cat. No.: HY-18944
CAS No.: 1113044-49-7
Research Areas:  

Infection

FIT-039 is a selective, ATP-competitive and orally active CDK9 inhibitor with an IC50 of 5.8 μM for CKD9/cyclin T1. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits replication of HSV-1 (IC50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses.
loading...
    loading...
Cat. No.: HY-123572
CAS No.: 171674-76-3
Purity:  96.07%
Synonyms: AG1717
Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .
loading...
    loading...
Cat. No.: HY-109106A
CAS No.: 2052969-18-1
Purity:  99.91%
Synonyms: SK-1403; AJT240; PLS240
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca 2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-13566AS
CAS No.: 1346598-22-8
Purity:  99.90%
Belotecan-d7 (hydrochloride) is the deuterium labeled Belotecan hydrochloride. Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative .
loading...
    loading...
Cat. No.: HY-14811
CAS No.: 251111-30-5
Synonyms: ZGN-440; CKD-732 free base
Target:  

MetAP NF-κB

Research Areas:  

Metabolic Disease

Beloranib (ZGN-440; CKD-732 free base) is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib can be used in research on obesity and hypothalamic obesity .
loading...
    loading...
Cat. No.: HY-14952
CAS No.: 865200-20-0
Purity:  99.68%
Synonyms: PLA-695
Giripladib (PLA-695) is a selective cPLA2α inhibitor. Giripladib attenuates CKD serum-induced PUFA accumulation, MDA and ROS levels, restores the GSH/GSSG ratio, and alleviates mitochondria-Ferroptosis-related morphological changes. Giripladib exhibits anti-inflammatory and disease-modifying effects in collagen-induced arthritis. Giripladib can be used in research on chronic kidney disease-associated plaque vulnerability, rheumatoid arthritis, and breast cancer .
loading...
    loading...